Open AccessCommunity-acquired CTX-M-15-type ESBL-producing Escherichia coli meningitis: a case report and literature review
Author(s) -
Nazif Elaldı,
Mustafa Gökhan Gözel,
Fetiye Kolaylı,
Aynur Engın,
Cem Çeli̇k,
Mustafa Zahir Bakıcı,
Haluk Vahaboğlu
Publication year - 2013
Publication title -
the journal of infection in developing countries
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.322
H-Index - 49
eISSN - 2036-6590
pISSN - 1972-2680
DOI - 10.3855/jidc.2820
Subject(s) - meropenem , amikacin , meningitis , imipenem , ciprofloxacin , medicine , microbiology and biotechnology , neonatal meningitis , cephalosporin , carbapenem , antibiotics , escherichia coli , pediatrics , biology , antibiotic resistance , biochemistry , gene
In this report, a case of community-acquired acute bacterial meningitis (CA-ABM) caused by CTX-M-15-producing Escherichia coli in an elderly male patient was presented in the light of literature. Cultures of cerebrospinal fluid, blood, ear discharge, and stool samples yielded CTX-M-15-producing E. coli in-vitro, which was resistant to the extended-spectrum cephalosporins and ciprofloxacin and susceptible to imipenem, meropenem and amikacin. Meningitis was treated with parenteral meropenem plus parenteral and intraventricular amikacin administration. Since bacterial meningitis is a life-threatening infection, empiric antibiotic therapy with carbapenem can be started before the culture results are obtained, mainly in areas where the ESBL epidemiology is well known.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom